comparemela.com

Latest Breaking News On - Food control - Page 19 : comparemela.com

Nearly 70% of private label avocado oil ranci

UC Davis researchers find that most private label avocado oils are rancid or mixed with other oils or additives.

United statesHilary greenSelina wangDepartment of food scienceAvocado oil expert groupAmerican oil chemist societyUniversity of californiaFood controlCooperative extensionFood science

Nearly 70% of private label avocado oil not fresh, mixed with other oils: Study

New York, May 25: Avocado oil has become a popular choice for many people in recent years because of its heart-healthy benefits and versatility in cooking. However, nearly 70 per cent of private label avocado oil is rancid and mixed with other oils, a study has revealed.

United statesNew yorkAkash madhwalJasprit bumrahSelina wangUniversity of californiaDepartment of food scienceFood controlCooperative extensionFood science

Nearly 70% of private label avocado oil not fresh, mixed with other oils: Study

Nearly 70% of private label avocado oil not fresh, mixed with other oils: Study
indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSelina wangUniversity of californiaDepartment of food scienceFood controlCooperative extensionFood science

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Indonesia National Agency of Drug and Food.

South koreaHong kongPeter qianJay meiAsia pacificThomas karalisHong kong stock exchangeIndonesia national agency of drugKaryopharm therapeutics incCompany annualAntengene corporation limitedNew drug applicationsIndonesia national agencyFood controlCorporate vice presidentKaryopharm therapeutics

Antengene Announces NDA Submission for XPOVIO in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In Q4 2022, Antengene also submitted NDAs for XPOVIO in Malaysia and Thailand. "In just six months, we have submitted NDAs for XPOVIO in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting our plans to expand commercial presence in the APAC region," said Thomas Karalis, Antengene's Corporate Vice President, Head of Asia Pacific Region. "In a region

South koreaHong kongAsia pacificPeter qianJay meiThomas karalisAntengene corporation limitedHong kong stock exchangeKaryopharm therapeutics incCompany annualIndonesia national agency of drugNew drug applicationsIndonesia national agencyFood controlCorporate vice presidentKaryopharm therapeutics

vimarsana © 2020. All Rights Reserved.